Allogene Therapeutics (ALLO) Share-based Compensation (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Share-based Compensation data on file, last reported at $8.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 32.07% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at -$3.9 million (down 106.35% YoY), and the FY2024 full-year result was $51.7 million, changed N/A from the prior year.
• Share-based Compensation improved to $8.3 million in Q1 2026, from -$12.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $36.5 million in Q3 2024 to a low of -$35.4 million in Q3 2023.
• A 5-year average of $7.0 million and a median of $12.9 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 267.22% in 2023 and surged 405.4% in 2025, its largest moves.
• Tracing ALLO's Share-based Compensation over 5 years: stood at -$35.0 million in 2022, then retreated by 1.06% to -$35.4 million in 2023, then jumped by 136.4% to $12.9 million in 2024, then tumbled by 194.58% to -$12.2 million in 2025, then surged by 167.93% to $8.3 million in 2026.
• Business Quant data shows ALLO's Share-based Compensation at $8.3 million in Q1 2026, -$12.2 million in Q2 2025, and $12.2 million in Q1 2025.